SC-006 is an experimental drug being developed by AbbVie
in collaboration with Stemcentrx, for treating patients with advanced
colorectal cancer (CRC).
AbbVie,
a global biopharmaceutical company, announced in April 2016 that it will
acquire Stemcentrx to further boost it’s oncology pipeline. SC-006 is a fruit
of the merger. Though the mechanism of action is not revealed, it could be directed
against DLL3 (delta-like protein 3) like SC-002.
 |
| New Drug for Treating Colorectal Cancer |
SC-006
is in Phase I clinical trials in patients with CRC as an intravenous dose regime.
References:
1. ClinicalTrials.gov A Study of SC-006 in
Subjects With Advanced Cancer. NCT03035279
